Skip to main content

Advertisement

Log in

Neuraminidase inhibitors in the management of influenza – experience of an outpatient practice

  • Clinical Practice
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract.

The neuraminidase inhibitors signifies a breakthrough in the treatment of influenza. We compared the outcomes of influenza in 56 patients treated with zanamivir or oseltamivir to a group of 52 influenza patients from the time before these drugs were available. The duration of illness was reduced by 45%, the severity of symptoms by 40% and the administration of antibiotics by 32%. The data from this small group of patients of our ambulatory practice correspond to the results of large randomized placebo-controlled double-blind studies on zanamivir and oseltamivir. Our clinical observations and painful experiences have taught us to take every case of suspected influenza seriously. Since considerable influenza-related complications are common even in otherwise healthy individuals, patients should immediately consult their doctor when an illness with sudden onset of fever and cough or another respiratory symptom occur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogel, G.E. Neuraminidase inhibitors in the management of influenza – experience of an outpatient practice. Med Microbiol Immunol 191, 161–163 (2002). https://doi.org/10.1007/s00430-002-0138-x

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-002-0138-x

Navigation